膀胱癌治療和診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、診斷、癌症類型、地區和競爭細分，2020-2030 年預測

2024 年全球膀胱癌治療和診斷市場價值為 4.5022 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 7.50%。當膀胱內壁的健康細胞（最常見的是尿路上皮細胞）發生不受控制的變化和擴張，形成稱為腫瘤的腫塊時，就會發展為膀胱癌。腎盂、輸尿管和尿道均覆蓋尿路上皮細胞。另一種尿路上皮癌稱為上尿路上皮癌，是起源於腎盂和輸尿管的癌症。其治療方法通常與本指南中討論的膀胱癌治療方法類似。腫瘤可能是良性的，也可能是惡性的。惡性是指癌性腫瘤具有發展並轉移到身體不同部位的能力。如果腫瘤是良性的，它可以增大但不會擴散。良性膀胱腫瘤很少發生。全球膀胱癌發生率不斷上升，尤其是在老年人口中，是一個重要促進因素。膀胱癌病例數量的不斷增加導致了患者數量的增加，從而推動了對診斷和治療的需求。

診斷技術的不斷改進，包括增強成像技術、尿液生物標記測試和基因分析，提高了膀胱癌的早期檢測和診斷能力，從而增加了對診斷的需求。免疫療法（例如檢查點抑制劑）和標靶療法等新型治療方法的發展擴大了膀胱癌患者的治療選擇並改善了其治療效果。這些創新推動了市場成長。正在進行的臨床試驗和研究計劃旨在探索新的治療方法、聯合療法和個人化醫療方法，為市場擴張創造了機會。全球人口老化使人們更容易罹患膀胱癌。隨著老年人口的成長，膀胱癌的盛行率預計會增加，導致對治療和診斷的需求增加。

主要市場促進因素

增加創新療法

主要市場挑戰

治療費用高昂

主要市場趨勢

微創手術技術

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球膀胱癌治療與診斷市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療方法（化療、免疫療法、其他療法）
  • 透過診斷（膀胱鏡檢查、膀胱超音波檢查、尿液分析、其他診斷）
  • 依癌症類型（膀胱移行細胞癌、膀胱鱗狀細胞癌、其他癌症類型）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：亞太地區膀胱癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲膀胱癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美膀胱癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲膀胱癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲膀胱癌治療和診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球膀胱癌治療與診斷市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson (Janssen Pharmaceutical)
• Merck & Co. Inc
• Astellas Pharma Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Bladder Cancer Therapeutics and Diagnostics Market was valued at USD 450.22 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2030. When healthy cells in the bladder lining most frequently urothelial cells change and expand uncontrollably, forming a mass known as a tumor, bladder cancer develops. The renal pelvis, ureters, and urethra are all lined with urothelial cells. Another form of urothelial cancer, known as upper tract urothelial carcinoma, is cancer that originates in the renal pelvis and ureters. It is often treated in a manner like that discussed in this guidance for bladder cancer. A tumor may be benign or malignant. Malignant refers to the ability of a cancerous tumor to develop and metastasize to different body regions. If a tumor is benign, it can enlarge but won't spread. Rarely do benign bladder tumors occur. A rising global incidence of bladder cancer, especially in aging populations, has been a significant driver. The growing number of bladder cancer cases creates a larger patient pool, driving demand for diagnostics and therapeutics.

Continuous improvements in diagnostic techniques, including enhanced imaging technologies, urine-based biomarker tests, and genetic profiling, have improved early detection and diagnosis of bladder cancer, thereby increasing the demand for diagnostics. The development of novel therapeutic approaches, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies, has expanded treatment options and improved outcomes for bladder cancer patients. These innovations drive market growth. Ongoing clinical trials and research initiatives to explore new treatments, combination therapies, and personalized medicine approaches create opportunities for market expansion. The aging global population is more susceptible to bladder cancer. As the elderly population grows, the prevalence of bladder cancer is expected to increase, leading to higher demand for therapeutics and diagnostics.

Key Market Drivers

Increasing Innovative Therapies

Innovative therapies in cancer therapeutics and diagnostics have transformed the way cancer is diagnosed and treated. These groundbreaking approaches offer new hope for patients and have the potential to improve outcomes while reducing side effects. For instance, according to Cancer Research UK, approximately 90% of bladder cancers in the UK are urothelial cancers, also called transitional cell cancers. Immunotherapy harnesses the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines are among the most promising approaches. These therapies have shown remarkable results in various cancers, including melanoma, lung cancer, and leukemia. Precision medicine, also known as personalized medicine, tailors cancer treatment based on a patient's genetic, genomic, and molecular profile. Targeted therapies, such as tyrosine kinase inhibitors and PARP inhibitors, are designed to specifically target the genetic mutations or abnormalities driving a patient's cancer. Gene therapy involves the introduction or modification of genes to treat or prevent diseases, including cancer. CAR-T cell therapy is a prime example, where a patient's T cells are genetically engineered to target cancer cells with precision. Cancer vaccines stimulate the immune system to recognize and attack cancer cells. Therapeutic cancer vaccines aim to treat existing cancer, while preventive vaccines, like the HPV vaccine, prevent certain cancers from developing. Liquid biopsies involve analyzing blood, urine, or other bodily fluids to detect cancer-specific biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These tests are minimally invasive and can provide insights into a patient's cancer status, treatment response, and minimal residual disease. Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow for highly targeted radiation delivery, minimizing damage to healthy tissue.

Key Market Challenges

High Treatment Costs

The financial burden associated with bladder cancer diagnosis and treatment affects not only patients but also healthcare systems and society. The diagnostic process for bladder cancer often includes multiple procedures, such as cystoscopy, imaging (CT scans, MRI), urine tests, and potentially invasive biopsies. These diagnostic tests and procedures can accumulate substantial costs. Bladder cancer treatment options vary depending on the stage and type of cancer. Treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of these approaches. Each of these treatment modalities carries its own cost implications. Surgical procedures for bladder cancer, whether open or minimally invasive, can be expensive. Costs include surgeon fees, operating room expenses, anesthesia, and hospitalization. Immunotherapy and targeted therapies, while offering promising outcomes, can be expensive due to the high cost of drug development and administration. Some of these treatments are administered over an extended period. External beam radiation therapy and brachytherapy are common treatments for bladder cancer. The cost of radiation therapy includes the use of specialized equipment and personnel. The cost of chemotherapy drugs, as well as the monitoring and management of side effects, can be a significant financial burden on patients and healthcare systems. Bladder cancer patients often require long-term surveillance and monitoring for recurrence. This includes regular check-ups, imaging, and urine tests, which can add to the overall cost of care.

Key Market Trends

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, often result in smaller incisions, less pain, and faster recovery times compared to open surgery. This leads to improved post-operative outcomes and a better quality of life for bladder cancer patients. Minimally invasive procedures typically require shorter hospital stays, reducing healthcare costs and freeing up hospital resources for other patients. Robotic-assisted surgery allows for precise removal of bladder tumors while preserving healthy tissue. This is especially important for patients with non-muscle-invasive bladder cancer (NMIBC) where tumor recurrence is a concern. Smaller incisions and reduced tissue trauma lower the risk of surgical site infections, which is a significant concern in open surgeries. Patients who undergo minimally invasive procedures often experience quicker recoveries, enabling them to return to their daily activities and work sooner. Minimally invasive techniques are associated with less pain and discomfort during the post-operative period, reducing the need for heavy pain medications. Smaller incisions result in less visible scarring, which can be particularly important for patients' body image and self-esteem. Laparoscopic and robotic systems provide surgeons with enhanced visualization of the surgical site, allowing for more precise tumor removal and reduced damage to healthy tissue.

Key Market Players

• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson (Janssen Pharmaceutical)
• Merck & Co. Inc
• Astellas Pharma Inc.

Report Scope:

In this report, the Global Bladder Cancer Therapeutics and Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics:

• Chemotherapy
• Immunotherapy
• Other Therapeutics

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics:

• Cystoscopy
• Bladder Ultrasound
• Urinalysis
• Other Diagnostics

Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type:

• Transitional Cell Bladder Cancer
• Squamous Cell Bladder Cancer
• Other Cancer Types

Bladder Cancer Therapeutics and Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Available Customizations:

Global Bladder Cancer Therapeutics and Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics)
  • 5.2.2. By Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)
  • 5.2.3. By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Diagnostics
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. India Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Australia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By Cancer Type
  • 6.3.4. Japan Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapeutics
      • 6.3.4.2.2. By Diagnostics
      • 6.3.4.2.3. By Cancer Type
  • 6.3.5. South Korea Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapeutics
      • 6.3.5.2.2. By Diagnostics
      • 6.3.5.2.3. By Cancer Type

7. Europe Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Diagnostics
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. Germany Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. Spain Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. United Kingdom Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By Cancer Type

8. North America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Diagnostics
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. Mexico Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Canada Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By Cancer Type

9. South America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Diagnostics
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. Argentina Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. Colombia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Diagnostics
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. UAE Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Bladder Cancer Therapeutics and Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bristol-Myers Squibb Company
• 16.3. Eli Lilly and Company
• 16.4. F. Hoffmann-La Roche Ltd
• 16.5. GlaxoSmithKline PLC
• 16.6. Novartis International AG
• 16.7. Pfizer Inc.
• 16.8. Abbott Inc.
• 16.9. Endo Pharmaceuticals Inc.
• 16.10.Johnson & Johnson (Janssen Pharmaceutical)
• 16.11. Merck & Co. Inc
• 16.12. Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer